{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:32:53Z","timestamp":1791300773339,"version":"4.1.0"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,1,1]]},"DOI":"10.1093\/cvr\/cvp281","type":"journal-article","created":{"date-parts":[[2009,8,13]],"date-time":"2009-08-13T21:24:27Z","timestamp":1250198667000},"page":"232-240","source":"Crossref","is-referenced-by-count":73,"title":["Hypoxia-induced pulmonary hypertension: comparison of soluble epoxide hydrolase deletion vs. inhibition"],"prefix":"10.1093","volume":"85","author":[{"given":"Benjamin","family":"Keser\u00fc","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Barbosa-Sicard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph T.","family":"Schermuly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromasa","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce D.","family":"Hammock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Weissmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beate","family":"Fisslthaler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Fleming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2009,8,13]]},"reference":[{"key":"key\n\t\t\t\t20170518142404_CVP281C1","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1152\/japplphysiol.00733.2004","article-title":"Hypoxic pulmonary vasoconstriction","volume":"98","author":"Moudgil","year":"2005","journal-title":"J Appl Physiol"},{"key":"key\n\t\t\t\t20170518142404_CVP281C2","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.1542\/pir.20-11-e91","article-title":"Mechanisms of structural remodeling in chronic pulmonary hypertension","volume":"20","author":"Durmowicz","year":"1999","journal-title":"Pediatr Rev"},{"key":"key\n\t\t\t\t20170518142404_CVP281C3","doi-asserted-by":"crossref","first-page":"L314","DOI":"10.1152\/ajplung.2001.281.2.L314","article-title":"Hypoxic pulmonary vasoconstriction: a multifactorial response?","volume":"281","author":"Weissmann","year":"2001","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"key\n\t\t\t\t20170518142404_CVP281C4","doi-asserted-by":"crossref","first-page":"5489","DOI":"10.1242\/jcs.02674","article-title":"Cytochrome P450 epoxygenases 2C8 and 2C9 are implicated in hypoxia-induced endothelial cell migration and angiogenesis","volume":"118","author":"Michaelis","year":"2005","journal-title":"J Cell Sci"},{"key":"key\n\t\t\t\t20170518142404_CVP281C5","doi-asserted-by":"crossref","first-page":"4306","DOI":"10.1096\/fj.08-112821","article-title":"Epoxyeicosatrienoic acids and the soluble epoxide hydrolase are determinants of pulmonary artery pressure and the acute hypoxic pulmonary vasoconstrictor response","volume":"22","author":"Keser\u00fc","year":"2008","journal-title":"FASEB J"},{"key":"key\n\t\t\t\t20170518142404_CVP281C6","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/FJC.0b013e3181506445","article-title":"The soluble epoxide hydrolase as a pharmaceutical target for hypertension","volume":"50","author":"Chiamvimonvat","year":"2007","journal-title":"J Cardiovasc Pharmacol"},{"key":"key\n\t\t\t\t20170518142404_CVP281C7","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1161\/01.RES.87.11.992","article-title":"Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids","volume":"87","author":"Yu","year":"2000","journal-title":"Circ Res"},{"key":"key\n\t\t\t\t20170518142404_CVP281C8","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.resuscitation.2007.06.031","article-title":"Soluble epoxide hydrolase gene deletion reduces survival after cardiac arrest and cardiopulmonary resuscitation","volume":"76","author":"Hutchens","year":"2008","journal-title":"Resuscitation"},{"key":"key\n\t\t\t\t20170518142404_CVP281C9","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1161\/HYPERTENSIONAHA.107.102160","article-title":"Altered soluble epoxide hydrolase gene expression and function and vascular disease risk in the stroke-prone spontaneously hypertensive rat","volume":"51","author":"Corenblum","year":"2008","journal-title":"Hypertension"},{"key":"key\n\t\t\t\t20170518142404_CVP281C10","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1161\/STROKEAHA.107.502179","article-title":"Genetic variation in soluble epoxide hydrolase (EPHX2) is associated with an increased risk of ischemic stroke in white Europeans","volume":"39","author":"Gschwendtner","year":"2008","journal-title":"Stroke"},{"key":"key\n\t\t\t\t20170518142404_CVP281C11","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1073\/pnas.0409591102","article-title":"Attenuation of tobacco smoke-induced lung inflammation by treatment with a soluble epoxide hydrolase inhibitor","volume":"102","author":"Smith","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"key\n\t\t\t\t20170518142404_CVP281C12","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1073\/pnas.0437724100","article-title":"The soluble epoxide hydrolase encoded by EPXH2 is a bifunctional enzyme with novel lipid phosphate phosphatase activity","volume":"100","author":"Newman","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"key\n\t\t\t\t20170518142404_CVP281C13","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1073\/pnas.0437829100","article-title":"The N-terminal domain of mammalian soluble epoxide hydrolase is a phosphatase","volume":"100","author":"Cronin","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"key\n\t\t\t\t20170518142404_CVP281C14","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1016\/S0006-2952(02)00952-8","article-title":"Structural refinement of inhibitors of urea-based soluble epoxide hydrolases","volume":"63","author":"Morisseau","year":"2002","journal-title":"Biochem Pharmacol"},{"key":"key\n\t\t\t\t20170518142404_CVP281C15","doi-asserted-by":"crossref","first-page":"3825","DOI":"10.1021\/jm070270t","article-title":"Orally bioavailable potent soluble epoxide hydrolase inhibitors","volume":"50","author":"Hwang","year":"2007","journal-title":"J Med Chem"},{"key":"key\n\t\t\t\t20170518142404_CVP281C16","doi-asserted-by":"crossref","first-page":"40504","DOI":"10.1074\/jbc.M008106200","article-title":"Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation","volume":"275","author":"Sinal","year":"2000","journal-title":"J Biol Chem"},{"key":"key\n\t\t\t\t20170518142404_CVP281C17","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1160\/TH05-02-0104","article-title":"Congenital erythropoietin over-expression causes \u2018anti-pulmonary hypertensive\u2019 structural and functional changes in mice, both in normoxia and hypoxia","volume":"94","author":"Weissmann","year":"2005","journal-title":"Thromb Haemost"},{"key":"key\n\t\t\t\t20170518142404_CVP281C18","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.resp.2003.10.003","article-title":"Basic features of hypoxic pulmonary vasoconstriction in mice","volume":"139","author":"Weissmann","year":"2004","journal-title":"Respir Physiol Neurobiol"},{"key":"key\n\t\t\t\t20170518142404_CVP281C19","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1042\/BJ20061328","article-title":"Mouse Cyp4a isoforms: enzymatic properties, gender- and strain-specific expression, and role in renal 20-hydroxyeicosatetraenoic acid formation","volume":"403","author":"Muller","year":"2007","journal-title":"Biochem J"},{"key":"key\n\t\t\t\t20170518142404_CVP281C20","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.bbagrm.2007.11.005","article-title":"Transcriptional regulation of the human soluble epoxide hydrolase gene EPHX2","volume":"1779","author":"Tanaka","year":"2008","journal-title":"Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms"},{"key":"key\n\t\t\t\t20170518142404_CVP281C21","doi-asserted-by":"crossref","first-page":"13S","DOI":"10.1016\/j.jacc.2004.02.029","article-title":"Cellular and molecular pathobiology of pulmonary arterial hypertension","volume":"43","author":"Humbert","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20170518142404_CVP281C22","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1161\/01.HYP.0000208299.62535.58","article-title":"Cytochrome P450 epoxygenase gene function in hypoxic pulmonary vasoconstriction and pulmonary vascular remodeling","volume":"47","author":"Pokreisz","year":"2006","journal-title":"Hypertension"},{"key":"key\n\t\t\t\t20170518142404_CVP281C23","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1161\/ATVBAHA.107.161190","article-title":"Cytochrome P450 2C9-induced angiogenesis is dependent on EphB4","volume":"28","author":"Webler","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"key\n\t\t\t\t20170518142404_CVP281C24","doi-asserted-by":"crossref","first-page":"H142","DOI":"10.1152\/ajpheart.00783.2006","article-title":"Cytochrome P-450 epoxygenases protect endothelial cells from apoptosis induced by tumor necrosis factor-alpha via MAPK and PI3K\/Akt signaling pathways","volume":"293","author":"Yang","year":"2007","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"key\n\t\t\t\t20170518142404_CVP281C25","doi-asserted-by":"crossref","first-page":"15671","DOI":"10.1074\/jbc.M110806200","article-title":"Cytochrome P450 2C9-induced endothelial cell proliferation involves induction of mitogen-activated protein (MAP) kinase phosphatase-1, inhibition of the c-Jun N-terminal kinase, and up-regulation of cyclin D1","volume":"277","author":"Potente","year":"2002","journal-title":"J Biol Chem"},{"key":"key\n\t\t\t\t20170518142404_CVP281C26","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.mvr.2004.06.001","article-title":"Cellular and molecular mechanisms of pulmonary vascular remodeling: role in the development of pulmonary hypertension","volume":"68","author":"Mandegar","year":"2004","journal-title":"Microvasc Res"},{"key":"key\n\t\t\t\t20170518142404_CVP281C27","doi-asserted-by":"crossref","first-page":"9018","DOI":"10.1073\/pnas.0703229104","article-title":"Angiotensin II up-regulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo","volume":"104","author":"Ai","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"key\n\t\t\t\t20170518142404_CVP281C28","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.prostaglandins.2006.05.004","article-title":"Soluble epoxide hydrolase inhibition reveals novel biological functions of epoxyeicosatrienoic acids (EETs)","volume":"82","author":"Inceoglu","year":"2007","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"key\n\t\t\t\t20170518142404_CVP281C29","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/HJH.0b013e32831aedfa","article-title":"Inhibition of the soluble epoxide hydrolase attenuates monocrotaline-induced pulmonary hypertension in rats","volume":"27","author":"Revermann","year":"2009","journal-title":"J Hypertension"},{"key":"key\n\t\t\t\t20170518142404_CVP281C30","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1006\/abbi.1993.1411","article-title":"cDNA cloning and expression of a soluble epoxide hydrolase from human liver","volume":"305","author":"Beetham","year":"1993","journal-title":"Arch Biochem Biophys"},{"key":"key\n\t\t\t\t20170518142404_CVP281C31","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1124\/mol.64.2.482","article-title":"Polymorphisms in human soluble epoxide hydrolase","volume":"64","author":"Przybyla-Zawislak","year":"2003","journal-title":"Mol Pharmacol"},{"key":"key\n\t\t\t\t20170518142404_CVP281C32","doi-asserted-by":"crossref","first-page":"36592","DOI":"10.1074\/jbc.M806315200","article-title":"Opposite regulation of cholesterol levels by the phosphatase and hydrolase domains of soluble epoxide hydrolase","volume":"283","author":"Enayetallah","year":"2008","journal-title":"J Biol Chem"},{"key":"key\n\t\t\t\t20170518142404_CVP281C33","doi-asserted-by":"crossref","first-page":"E375","DOI":"10.1152\/ajpendo.00131.2009","article-title":"Alteration in plasma testosterone levels in male mice lacking soluble epoxide hydrolase","volume":"297","author":"Luria","year":"2009","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"key\n\t\t\t\t20170518142404_CVP281C34","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.bbrc.2005.12.180","article-title":"Effects of human soluble epoxide hydrolase polymorphisms on isoprenoid phosphate hydrolysis","volume":"341","author":"Enayetallah","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"key":"key\n\t\t\t\t20170518142404_CVP281C35","doi-asserted-by":"crossref","first-page":"12179","DOI":"10.1021\/bi050842g","article-title":"Lipid sulfates and sulfonates are allosteric competitive inhibitors of the N-terminal phosphatase activity of the Mammalian soluble epoxide hydrolase","volume":"44","author":"Tran","year":"2005","journal-title":"Biochemistry"},{"key":"key\n\t\t\t\t20170518142404_CVP281C36","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0163-7827(02)00002-4","article-title":"Central role of peroxisomes in isoprenoid biosynthesis","volume":"41","author":"Kovacs","year":"2002","journal-title":"Prog Lipid Res"},{"key":"key\n\t\t\t\t20170518142404_CVP281C37","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1161\/01.HYP.0000153792.29478.1d","article-title":"Soluble epoxide hydrolase is a main effector of angiotensin II-induced hypertension","volume":"45","author":"Jung","year":"2005","journal-title":"Hypertension"},{"key":"key\n\t\t\t\t20170518142404_CVP281C38","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1097\/01.fjc.0000189600.74157.6d","article-title":"An epoxide hydrolase inhibitor, 12-(3-adamantan-1-yl-ureido)dodecanoic acid (AUDA), reduces ischemic cerebral infarct size in stroke-prone spontaneously hypertensive rats","volume":"46","author":"Dorrance","year":"2005","journal-title":"J Cardiovasc Pharmacol"}],"container-title":["Cardiovascular Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cardiovascres\/article-pdf\/85\/1\/232\/17199293\/cvp281.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,21]],"date-time":"2019-05-21T20:32:11Z","timestamp":1558470731000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cardiovascres\/article-lookup\/doi\/10.1093\/cvr\/cvp281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8,13]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2009,8,13]]},"published-print":{"date-parts":[[2010,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/cvr\/cvp281","relation":{},"ISSN":["1755-3245","0008-6363"],"issn-type":[{"value":"1755-3245","type":"electronic"},{"value":"0008-6363","type":"print"}],"subject":[],"published":{"date-parts":[[2009,8,13]]}}}